ACHC Price Prediction Next Week
Analysis and Insights
News Sentiment and Recent Developments:
Acadia Healthcare (ACHC) has shown mixed sentiment in recent news. While analysts maintain a Moderate Buy consensus with a price target of $48.78, indicating a 70.1% upside potential, the stock experienced a 6% decline in pre-market trading following the announcement of a $550 million senior notes offering. This decline may reflect short-term investor concerns about debt levels and financial leverage.
Technical Analysis:
The stock is currently trading at $29.06, near its 52-week low of $29.19. Key technical indicators suggest the stock is oversold:
- RSI (6-period): 30.84 (below 30, indicating oversold conditions).
- MACD: -3.00 (bearish momentum, but the MACD histogram shows early signs of stabilization at 0.19).
- Stochastic Oscillator: %K at 30.85 and %D at 24.06, both in oversold territory.
- Fibonacci Levels: The stock is trading near the S1 support level of $27.89, with a pivot point at $29.35. The next resistance levels are at $30.81 (R1) and $31.71 (R2).
Price Prediction and Recommendation:
Given the oversold conditions and positive analyst sentiment, ACHC is likely to experience a short-term rebound. The stock is expected to test the R1 level of $30.81 next week, with a potential upside to $31.50 if it breaks above this resistance.
Prediction: $31.50
Recommendation: Buy
ACHC Similar Chart Price Prediction
The price of ACHC is predicted to go up -9.26%, based on the high correlation periods with TSCO. The similarity of these two price pattern on the periods is 99.62%.
ACHC
TSCO
Down: -9.26%Similarity: 99.62%
ACHC Revenue Forecast
ACHC EPS Forecast
ACHC FAQs
What is ACHC revenue forecast for next quarter？
What is ACHC eps forecast for next quarter？
ACHC Analyst's Forecast
Ben Hendrix
RBC Capital
Buy
2025-03-03
Price Target
$64 → $43
Upside
+46.43%
RBC Capital lowered the firm's price target on Acadia Healthcare to $43 from $64 and keeps an Outperform rating on the shares after its Q4 earnings miss. The stock fell off on Friday followed weaker than expected 2025 guidance, with an EBITDA range below the firm's Street-low estimate, as well as a revised multi-year outlook suggesting a notable reset of intermediate-term margin expectations, the analyst tells investors in a research note. The firm remains at Outperform on "atypically depressed" valuation, but also "feels less inclined" at this point to demand a premium to historical acute care hospital multiples, RBC added.
Matthew Gillmor
Keybanc
Buy
2025-03-03
Price Target
$70 → $65
Upside
+121.35%
Ryan Langston
TD Cowen
Strong Buy
2025-01-07
Price Target
$70 → $66
Upside
+45.66%
